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compensate for its deficiency. Expression of LRH-1 in fetal 
testis suggests a role in male gonadal development. How-
ever, as we found no  NR5A2 /LRH-1 mutations, the ‘second 
genetic hit’ in SF-1 patients explaining the broad phenotyp-
ic variability remains elusive.  © 2015 S. Karger AG, Basel 
 Steroidogenic factor-1 (SF-1, encoded by the  NR5A1 
gene) regulates adrenal and sex development and func-
tion [Schimmer and White, 2010].  NR5A1 mutations 
manifest in patients with a very variable phenotype and 
are frequently detected in 46,XY individuals with disor-
ders of sex development (DSD) and in 46,XX women with 
normal sexual development but primary ovarian insuffi-
ciency [Lourenço et al., 2009; Camats et al., 2012]. So far, 
no genotype-structure-function-phenotype correlation 
has been found for SF-1 variants. For  NR5A1 , identical 
mutations within families may lead to different pheno-
types [Lourenço et al., 2009; Camats et al., 2012], and so-
called severe mutations do not always cause a severe phe-
notype in patients [Camats et al., 2012]. Furthermore, al-
though the DSD and ovarian insufficiency phenotypes 
are mostly caused by heterozygote mutations, no domi-
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 Abstract 
 Steroidogenic factor 1 ( NR5A1 /SF-1)  mutations usually mani-
fest in 46,XY individuals with variable degrees of disordered 
sex development and in 46,XX women with ovarian insuffi-
ciency. So far, there is no genotype-phenotype correlation. 
The broad spectrum of phenotype with  NR5A1 mutations 
may be due to a second hit in a gene with similar function to 
 NR5A1 /SF-1. Liver receptor homologue-1 (LRH-1/ NR5A2 ) 
might be a good candidate. We performed in vitro  studies 
for the interplay between SF-1, LRH-1 and DAX-1, expression 
profiles in human steroidogenic tissues, and  NR5A2  genetic 
studies in a cohort (11 patients, 8 relatives, 11 families) har-
boring heterozygote  NR5A1 /SF-1 mutations. LRH-1 isoforms 
transactivate the  CYP17A1  and  HSD3B2 promoters similarly 
to SF-1 and compensate for SF-1 deficiency. DAX-1 inhibits 
SF-1- and LRH-1-mediated transactivation. LRH-1 is found 
expressed in human adult and fetal adrenals and testes. 
However, no  NR5A2 /LRH-1 mutations were detected in 14 
individuals with heterozygote  NR5A1 /SF-1 mutations. These 
findings demonstrate that in vitro LRH-1 can act like SF-1 and 
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nant negative effect has been detected [Camats et al., 
2012]. Therefore, the broad phenotype of  NR5A1/ SF-1 
mutations remains a conundrum.
 The SF-1 interactome comprises a large number of 
transcriptional, postranslational and signaling (co-)mod-
ulators [Hoivik et al., 2010; Schimmer and White, 2010]. 
SF-1 interacts with numerous genes including develop-
mental switches [Schimmer and White, 2010] and epi-
genetic factors [Hoivik et al., 2013]. Thus, the broad phe-
notype of  NR5A1  mutations may be due to a second hit 
in an interacting gene with similar function to SF-1. A 
double hit in both genes would then cause the severe phe-
notype, while a heterozygote  NR5A1  mutation alone 
would only cause a milder phenotype or even be compen-
sated fully by the second gene when normal. We chose 
liver receptor homolog-1 (LRH-1, encoded by  NR5A2 
gene) for our ‘second hit’ candidate for the following rea-
sons: (1) both transcription factors LRH-1 and SF-1 be-
long to the same NR5A family of transcription factors 
[Fayard et al., 2004], (2) they have a high sequence simi-
larity [Fayard et al., 2004], (3) both bind to the same pro-
moter-binding cis-elements [Wang et al., 2001; Kim et al., 
2004; Dubé et al., 2009], (4) they share common target 
steroidogenic genes [Wang et al., 2001; Sirianni et al., 
2002; Peng et al., 2003; Fayard et al., 2004; Kim et al., 2004, 
2005; Yazawa et al., 2009], and (5) both have a partially 
overlapping tissue expression pattern [Sirianni et al., 
2002; Falender et al., 2003]. To date, no human mutations 
in  NR5A2 have been described and, to our knowledge, no 
DSD patients have been analyzed for  NR5A2  sequence 
variations.
 LRH-1 and SF-1 share target genes related to steroido-
genesis and sex development such as  STAR  [Sirianni et 
al., 2002; Kim et al., 2004; Dubé et al., 2009],  CYP11A1 
 [Kim et al., 2005],  CYP17A1 [Wang et al., 2001; Sirianni 
et al., 2002; Yazawa et al., 2009],  HSD3B2 [Peng et al., 
2003; Dubé et al., 2009],  CYP19A1 [Dubé et al., 2009], 
 CYP11B1 [Sirianni et al., 2002],  CYP11B2 [Sirianni et al., 
2002], and  WNT4 [Zhang et al., 2013]. In females, LRH-1 
seems to play a major role in follicle maturation, ovula-
tion and pregnancy [Duggavathi et al., 2008; Zhang et al., 
2013], while its role in males is still poorly understood 
[Pezzi et al., 2004; Guo et al., 2007; Sierens et al., 2010]. 
SF-1 and LRH-1 are coexpressed in human non-steroido-
genic tissues (liver, pancreas and pituitary) [Li et al., 1998; 
Wang et al., 2001; Sirianni et al., 2002; Falender et al., 
2003], and steroidogenic tissues (adrenals, testes, ovaries, 
and placenta) [Wang et al., 2001; Sirianni et al., 2002; Fal-
ender et al., 2003; Peng et al., 2003; Yazawa et al., 2009; 
Zhang et al., 2013]. LRH-1 is less expressed in adrenals 
than SF-1 [Sirianni et al., 2002; Falender et al., 2003; Yaza-
wa et al., 2009]. SF-1 is highly expressed in all 3 steroido-
genic tissues (adrenals > testes > ovaries) [Yazawa et al., 
2009]. The expression pattern of SF-1 and LRH-1 within 
the gonads is complex [Sirianni et al., 2002]. In the ovary, 
SF-1 is expressed mainly in follicular theca and interstitial 
Human
Mouse
Rat
hLRH-1 TV1
mlrh1v1
mlrh1v2
rlrh1v1
1 92 4 5 7 86
1´
1´
9´3´2´ 4´ 5´ 7´ 8´6´
9´3´2´A 4´ 5´ 7´ 8´6´
9´3´2´ 4´ 5´ 7´ 8´6´
hLRH-1 TV2
hLRH-1 TV3
hLRH-1 TV4
1 94 5 7 86
94 53 7 86
942o 5 7 86
 Fig. 1. Reported human and rodent LRH-1 
transcripts. The schemes of 4 human and 3 
rodent LRH-1 transcripts are shown 
(http://www.ncbi.nlm.nih.gov/) [Gao et 
al., 2006; Kawabe et al., 2013]. Dashed lines 
indicate the location of the PCR fragments 
amplified for the expression study. 
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cells in rodents [Ikeda et al., 1993; Falender et al., 2003; 
Liu et al., 2003] and human [Peng et al., 2003; Sato et al., 
2003]. In contrast, LRH-1 is expressed mainly in follicular 
granulosa cells and the corpus luteum in rodents [Liu et 
al., 2003] and human [Peng et al., 2003]. In the human 
adult testis, the expression of SF-1 and LRH-1 is also cell-
type specific and partially overlapping: Leydig cells ex-
press both SF-1 and LRH-1, Sertoli cells express SF-1, and 
germ cells (spermatocytes/spermatids) express LRH-1 
[Yazawa et al., 2009]. Whether LRH-1 is expressed in the 
human fetal testis has not yet been investigated.
 LRH-1 was cloned and characterized from human liv-
er tissues [Li et al., 1998]. Initially, 3 different isoforms 
were described which derive from alternative splicing in 
adult and fetal human liver [Li et al., 1998; Zhang et al., 
2001; Fayard et al., 2004] ( fig. 1 ). Isoforms 1 and 2 (iso-
form 2 lacks exon 2) are considered active [Li et al., 1998] 
and are expressed in the human liver [Li et al., 1998] and 
in the rat testis [Pezzi et al., 2004]. Lately, a new isoform 
3 has been entered in the NCBI database, which has not 
been further investigated so far ( fig. 1 ). This variant has 
an alternate exon (exon 3) instead of exons 1 and 2, has a 
downstream translation start site in exon 4 and is shorter 
than isoforms 1 and 2. Yet another human isoform con-
fined to granulosa cells (gc-LRH-1-2c) was recently re-
ported [Kawabe et al., 2013]. This isoform contains a larg-
er exon 2 formed by usage of an alternative transcription 
start site [Kawabe et al., 2013]. Additional 3 isoforms 
were found in embryogenic stem cells of mice and rats 
[Gao et al., 2006].
 DAX-1 is a global negative transcriptional regulator of 
steroidogenesis [Lalli and Sassone-Corsi, 2003]. The ex-
pression pattern of DAX-1 is restricted to tissues directly 
involved in sexual determination, steroidogenesis and re-
productive function [Ikeda et al., 1996; Hanley et al., 
2001; Lalli and Sassone-Corsi, 2003; Sato et al., 2003]. 
DAX-1 expression is coincidental to SF-1 tissue expres-
sion [Lalli and Sassone-Corsi, 2003] and, in part, also to 
LRH-1 tissue expression in granulosa cells [Kawabe et al., 
2013] and in Leydig cells [Yazawa et al., 2009]. DAX-1 has 
a specific function in distinct cell populations in male and 
female gonads [Lalli and Sassone-Corsi, 2003]. Its activ-
ity seems essential for gonadal development in males, but 
dispensable in females [Lalli and Sassone-Corsi, 2003]. 
DAX-1 represses SF-1 [Hanley et al., 2001; Iyer and Mc-
Cabe, 2004] and LRH-1 [Kim et al., 2004] transactivation 
activity via protein-protein interaction [Ito et al., 1997; 
Hanley et al., 2001; Suzuki et al., 2003]. At the same time, 
SF-1 stimulates transcription of DAX-1 [Hoyle et al., 
2002], thereby inhibiting its own expression. Moreover, 
SF-1 and LRH-1 regulate LRH-1 expression via promoter 
activation [Kawabe et al., 2013]. Overall, a complex tri-
angular relationship between DAX-1, SF-1 and LRH-1 
seems to play an important role in steroidogenesis and 
sex development.
 This study aimed to elucidate the underlying cause for 
the broad phenotype of human  NR5A1 /SF-1 mutations. 
LRH-1 was hypothesized to be a modulator of SF-1 being 
able to replace its function in case of deficiency. To ad-
dress this hypothesis, the ability of LRH-1 to transactivate 
steroidogenic promoter reporters in vitro was assessed 
and compared to wild-type and mutant SF-1, including 
their interplay with DAX-1. LRH-1 expression profiles 
were assessed for human adult and fetal adrenal and testis 
tissues. Finally, genetic studies for  NR5A2 /LRH-1 muta-
tions were performed in a cohort of 14 individuals har-
boring heterozygote  NR5A1 /SF-1 mutations and 5 non-
carrier relatives.
 Patients and Methods 
 Genetic Analyses 
 For the genetic studies, written informed consent was obtained 
from all individual participants/legal guardians included in the 
study after full explanation of the purpose and nature of all the 
procedures used. The study was approved by the respective ethical 
committees of the University Hospital Bern, Switzerland and the 
Vall d’Hebrón University Hospital in Barcelona, Spain.
 The  NR5A2 gene was sequenced in a cohort of 11 families with 
heterozygote  NR5A1 mutations and 10 were previously described 
[Camats et al., 2012]. All exon sequences and their flanking in-
tronic sequences of the  NR5A2 (LRH-1) gene were amplified 
by PCR, using specific primers (online suppl. table 1; see www.
karger.com/doi/10.1159/000381575). PCR products from  NR5A2 
 were sequenced using the BigDyeTerminator v3.1 Cycle Sequenc-
ing Kit on an automated ABI PRISM 3100 Genetic Analyzer (Ap-
plied Biosystems, Foster City, Calif., USA). Primers used for PCR 
were also employed for sequencing (online suppl. table  1). Ob-
tained sequences were analyzed against GenBank entry 
NC_000001.10  (NR5A2) . Hardy–Weinberg equilibrium was test-
ed for SNPs presenting 3 alternate genotypes according to stan-
dard procedures using the χ 2 test. Linkage disequilibrium between 
individual SNPs was calculated as the correlation coefficient be-
tween pairs.
 Plasmids and Cloning 
 Promoter luciferase reporter vectors -3.7kbCYP17A1_Δluc, 
-1050HSD3B2_pGL3 and empty control vectors (Δluc, pGL3) 
were available from previous work [Huang and Miller, 2000; Flück 
and Miller, 2004]. Wild-type (WT) SF-1/ NR5A1 _pcDNA3 and 
V20L-mutant SF-1/ NR5A1 _pcDNA3 mammalian expression vec-
tors were also available from previous work [Camats et al., 2012]. 
LRH-1/ NR5A2 _pCMX vectors (in this study named isoform 1/
TV1 and isoform 2/TV2) were kindly provided by Dr. Schoonjans 
(École Polytechnique Fédérale, Lausanne, Switzerland), and hu-
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man ovarian gc-LRH1 (in this study named isoform 4/TV4) vector 
was kindly provided by Dr. Yazawa (Faculty of Medical Sciences, 
Translational Research Center, University of Fukui, Fukui, Japan). 
The DAX-1 cDNA (NCBI NM_000475.4) was obtained by RT-
PCR from RNA of human adrenal NCI-H295R cells (ATCC CRL-
2128 TM ) and cloned into the pcDNA3 mammalian expression vec-
tor (Invitrogen AG, Basel, Switzerland). Used primers are listed in 
online supplementary table 1.
 In vitro Studies 
 Promoter activity experiments were performed in non-ste-
roidogenic, human embryonic kidney cells HEK293 as previously 
described [Camats et al., 2012]. In brief, cells were cultured in 
DMEM, supplemented with 10% fetal calf serum, 1% penicillin/
streptomycin and 1% sodium pyruvate (Gibco, Paisley, UK). For 
transfection, cells were cultured on 24-well plates and transiently 
transfected with WT SF-1 and/or V20L SF-1, and/or LRH-1 iso-
forms 1, 2, or 4 and/or DAX-1 expression vectors together with 
 CYP17A1  or  HSD3B2  promoter luciferase reporter constructs us-
ing Lipofectamine 2000 TM (Invitrogen). One μg of promoter lucif-
erase vectors and 0.25 μg mammalian expression vectors were 
transfected per duplicate (4: 1). In the experiments including 2 
mammalian expression vectors, they were transfected in a propor-
tion 1: 1 (0.125 μg each). Forty-eight hours after transfection, cells 
were washed with PBS, lysed and assayed for luciferase activity 
with the Dual-Luciferase Reporter (DLR TM ) Assay System (Pro-
mega AG, Wallisellen, Switzerland) on a Veritas microplate Lumi-
nometer reader (Turner BioSystems Luminometer and Software 
by Promega). Specific Firefly luciferase readings were standardized 
against Renilla control readings. Experiments were repeated 2–5× 
in duplicates, and data were summarized giving the mean ± SD. 
Statistical significance was calculated using an unpaired t-test with 
Prism 4 (Graphpad software) and Microsoft Excel. Significance 
was defined as p  ≤ 0.05.
 Gene Expression Studies 
 Adrenal and testicular tissue cDNA samples were all purchased 
from Amsbio (AMS Biotechnology (Europe) Limited, Abingdon, 
UK) and originated each from 4 healthy individuals. cDNA ob-
tained from HepG2 cells (ATCC HB 8065 TM ) served as control. 
Semiquantitative PCRs for LRH-1 (isoforms 1, 2, 3, and 4), SF-1, 
DAX-1, and GAPDH (35 cycles, n = 3) were carried out using the 
recommended concentrations of the purchased cDNAs and 50 ng 
for the HepG2 cDNA. Primers used are listed in online supplemen-
tary table 1, and the location of the corresponding PCR fragments 
are depicted in  figure 1 . PCR products were electrophoresed on an 
agarose gel and detected by ethidium bromide on a UV transillu-
minator (Alphaimager, Proteinsimple, Santa Clara, Calif., USA).
 Results 
 Both LRH-1 and SF-1 Can Transactivate 
Steroidogenic Promoters 
 The ability of LRH-1 isoforms 1, 2 and 4 (TV1, 2, 4) to 
activate steroidogenic enzyme promoters was tested and 
SF-1Ve TV1 TV2 TV4
LRH-1
CYP17A1 CYP17A1
0
50
100
150
200
250
FO
V
** **
**
+
–
–
–
++
–
+
TV2
+
TV1
+
TV4
0
50
100
150
200
250
FO
V
** ***
*
a
SF-1
LRH-1
SF-1Ve TV1 TV2 TV4
LRH-1
HSD3B2 HSD3B2
0
10
20
30
40
FO
V *
+
–
–
–
++
–
+
TV2
+
TV1
+
TV4
0
5
10
15
20
FO
V
*
b
SF-1
LRH-1
 Fig. 2. LRH-1 can activate the steroidogen-
ic  CYP17A1 and  HSD3B2 promoters. The 
ability of LRH-1 isoforms 1, 2 and 4 to ac-
tivate steroidogenic enzyme promoter lu-
ciferase reporter constructs was tested in 
non-steroidogenic HEK293 cells and com-
pared to WT SF-1. Cells were transiently 
transfected with  NR5A1 /SF-1 and  NR5A2 /
LRH-1 expression vectors either alone 
or in combination, and together with a 
 CYP17A1 ( a ) or  HSD3B2 ( b ) promoter re-
porter construct. Luciferase activity was 
measured with the Promega Dual Lucifer-
ase assay system. Results are expressed as 
fold over empty vector (FOV), and repre-
sent the mean and SD of 2 to 5 independent 
experiments performed in duplicate.  * p  < 
 0.05,  * * p  <  0.01. LRH-1 isoforms are all 
WT. 
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compared to WT SF-1 ( fig. 2 ). HEK cells were transiently 
transfected with  NR5A1 /SF-1 or  NR5A2 /LRH-1 (TV1, 2, 
4) in combination with a  CYP17A1 ( fig. 2 a) or  HSD3B2 
( fig.  2 b) promoter reporter. These assays showed that 
all LRH-1 isoforms are able to transactivate both the 
 CYP17A1 and the  HSD3B2 promoters. Compared to SF-1, 
this transactivation seems to be weaker on the  CYP17A1 
promoter than on the  HSD3B2 promoter, where similar 
results for LRH-1 and SF-1 were found. When transfecting 
cells with both SF-1 and LRH-1 mimicking homozygosity 
or double effect of heterozygosity for SF-1 and LRH-1, we 
found no additional effect, neither for double dosage SF-1 
nor for the combination of SF-1 with any of the transcript 
variants of LRH-1 on both the  CYP17A1 ( fig. 2 a) and the 
 HSD3B2 ( fig. 2 b) promoters. Only LRH-1 TV4 seemed to 
impair the effect of SF-1 on  CYP17A1 promoter activity.
 DAX-1 Inhibits Not Only SF-1 but Also 
LRH-1-Mediated Transactivation 
 DAX-1 is a well-known SF-1 modulator [Hanley et al., 
2001; Iyer and McCabe, 2004]. Therefore, we wondered 
whether DAX-1 also modulates the effect of LRH-1 on 
transcription. HEK293 cells were transiently transfected 
with  NR5A2 /LRH-1 or  NR5A1 /SF-1 with or without 
DAX-1 and  CYP17A1  or  HSD3B2  promoter reporters 
( fig. 3 ). As expected, we found that DAX-1 impaired the 
effect of SF-1 on the  CYP17A1 promoter, less so on the 
 HSD3B2 promoter. Similarly, DAX-1 was able to inhib-
it the effect of all tested LRH-1 variants on both the 
 CYP17A1 and the  HSD3B2 promoters. In general, this 
inhibitory effect of DAX-1 was even stronger with LRH-1 
partners than with SF-1.
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 Fig. 3. The interplay between LRH-1, SF-1 and DAX-1 on pro-
moter activities of steroidogenic genes. The ability of SF-1 and 
LRH-1 isoforms 1, 2 and 4 to activate steroidogenic enzyme pro-
moter luciferase reporter constructs under the influence of DAX-1 
was tested in non-steroidogenic HEK293 cells. Cells were tran-
siently transfected with  NR5A1 /SF-1 or  NR5A2 /LRH-1 expression 
vectors with or without the DAX-1 expression vector and with the 
 CYP17A1  ( a ) or the  HSD3B2 ( b ) promoter reporter. Luciferase 
activity was measured with the Promega Dual Luciferase assay sys-
tem. Results are expressed as described in figure 2.  * p  <  0.05, 
 * * p  <  0.01. LRH-1 isoforms are all WT. 
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 LRH-1 Can Rescue Mutant SF-1 in vitro 
 The V20L SF-1 /NR5A1 mutation was originally de-
tected in heterozygote state in a family with a severely af-
fected 46,XY DSD patient and a nonaffected carrier father 
representing the broad phenotype of  NR5A1  mutations. 
In previous studies, we showed that mutant V20L SF-1 
loses almost all transactivation activity on the  CYP17A1 
and  HSD3B2 promoters in HEK293 cells, and that co-
transfection with WT SF-1 fully restores this activity [Ca-
mats et al., 2012]. Therefore, we were interested whether 
LRH-1 might also be able to rescue mutant SF-1 function. 
For that, HEK293 cells were again transfected with LRH-
1 and the steroid enzyme promoter reporters, but this 
time with mutant V20L SF-1 ( fig. 4 ). For  CYP17A1 , only 
LRH-1 isoform 4 was able to rescue some  CYP17A1 ac-
tivity compared to WT SF-1 ( fig.  4 a). By contrast, for 
 HSD3B2 , we found that all LRH-1 isoforms were able to 
rescue the loss of function of mutant SF-1 similar to WT 
SF-1 ( fig. 4 b). The lowest effect was observed with LRH-1 
isoform 2.
 Gene Expression Pattern of SF-1 and LRH-1 in 
Human Steroidogenic Tissues 
 If LRH-1 and SF-1 collaborate for steroidogenesis, it is 
of interest how they are expressed in steroid producing 
tissues total. Therefore, we characterized the expression 
profile of LRH-1 and isoforms 1, 2, 3, and 4 in human 
adult and fetal adrenal and testicular tissues and com-
pared it with the expression profiles of SF-1 and DAX-1. 
For this, we performed RT-PCRs using commercially 
available  cDNAs of human tissues and HepG2 cDNA as 
control ( fig. 5 ). A scheme of the 4 human and of the 3 ro-
dent LRH-1 isoforms is shown in  figure 1 . LRH-1, SF-1 
and DAX-1 were expressed in all investigated tissues 
( fig. 5 ). We describe the expression of LRH-1 in the hu-
man fetal testis for the first time. LRH-1 isoform 1 is ex-
pressed in all 4 tissues, lowest in the adult testis. Isoform 
2 was difficult to assess and was finally only found in the 
fetal adrenal, but this might be a technical problem. Iso-
form 3 seems to be expressed at low levels in the adult 
adrenal and fetal testis. Interestingly, in contrast to other 
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 Fig. 4. LRH-1 can rescue SF-1 deficiency in 
vitro. Mutation V20L SF-1 loses almost all 
transcriptional activity on the  CYP17A1 
and  HSD3B2 promoters [Camats et al., 
2012]. Therefore, the ability of LRH-1 iso-
forms 1, 2 and 4 to rescue transactivation 
activity of V20L SF-1 on steroidogenic pro-
moter reporters was tested in non-ste-
roidogenic HEK293 cells and compared to 
WT SF-1. Cells were transiently transfect-
ed with  NR5A1 /SF-1 and  NR5A2 /LRH-1 
expression vectors and  CYP17A1 ( a ) and 
 HSD3B2 ( b ) promoter reporter constructs. 
Luciferase activity was measured with the 
Promega Dual Luciferase assay system. Re-
sults are expressed as described in figure 2. 
 * p <  0.05,  * * p  <  0.01. LRH-1 isoforms are 
all WT. 
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investigators [Kawabe et al., 2013], we found isoform 4 
expressed in HepG2 cells. LRH-1 isoform 4, which is 
thought to be confined to the ovary [Kawabe et al., 2013], 
is also expressed in both adult and fetal adrenal tissues, 
and at low levels in adult and fetal testis.
 No NR5A2 Mutations Were Detected in Patients with 
Heterozygote NR5A1 Mutations 
 We hypothesized that a second hit in the  NR5A2/ LRH-1 
gene may be responsible for the broad phenotype seen in 
patients with heterozygote  NR5A1/ SF-1 mutations. Ac-
cordingly, the  NR5A2 gene was studied in our cohort of 
11 families with heterozygote NR5A1 mutations includ-
ing 11 patients (ten 46,XY DSD patients and one 46,XX 
woman with ovarian insufficiency) and 8 relatives (3 car-
riers and 5 noncarriers) ( table 1 ) [Camats et al., 2012]. 
Noncoding exon 3, which corresponds to isoform 3 with 
unknown function (http://www.ncbi.nlm.nih.gov), was 
not studied. Overall, genetic analysis of the  NR5A2 gene 
in our cohort did not reveal any mutations neither in the 
exons nor in their boundaries ( table 1 ). We detected 11 
sequence variants, 3 in exons and 8 in introns. These vari-
ants were considered SNPs as they were found in the 
NCBI dbSNP database (http://www.ncbi.nlm.nih.gov/
snp). In one individual, an additional intronic change in 
IVS1 (c.65–33C>T) was detected which was not included 
in the dbSNP (sister 3;  table 1 ). The 3 exonic SNPs were 
silent changes (Lys111=; Pro250=; Asn523=). Three out 
of 8 intronic variants were located within the splicing-
machinery region, and one of these (c.1230+14C>T, 
IVS7) was present as heterozygote and alternate homozy-
gote in patients but also in their healthy relatives. Two 
patients presented the ancestral homozygote pattern for 
all the  NR5A1  sequence variants (patients 4 and 7); some 
patients had only few heterozygote changes, whereas oth-
ers accumulated several alternate homozygote changes 
(patients 2, 5, 8, and 9).
 NR5A2 genotype and allele frequencies were calculat-
ed for 11 affected  NR5A1/ SF-1 patients ( table 1 ). The two 
IVS7 SNP genotypes were in linkage disequilibrium 
(82%). The SNPs were not considered relevant because 
they were found too frequently in the normal population, 
although 3 alternate homozygote genotypes (in IVS7 and 
IVS8) were more frequent in our population than in pub-
lished data from several databases ( table 1 ).
 Discussion 
 Genotype-phenotype correlation for  NR5A1 /SF-1 
mutations remains unsolved [Camats et al., 2012]. A sec-
ond hit in another gene might explain the broad range of 
clinical manifestation. In our study, we therefore ad-
dressed the question whether the second hit is in the 
 NR5A2 /LRH-1 gene because LRH-1 is a close family 
member of SF-1 and has known regulatory functions in 
steroidogenesis [Sirianni et al., 2002; Dubé et al., 2009; 
Yazawa et al., 2009]. In our cell model, we found that 
LRH-1 has similar transactivational activity on steroid 
enzyme promoters as SF-1, that it interacts with DAX-1 
leading to a repression of transactivation, and that both 
LRH-1 and SF-1 wild-types are able to compensate for 
V20L SF-1, a previously shown severe loss of function 
 NR5A1  mutation. In addition, we characterized the tissue 
expression of LRH-1 in fetal and adult adrenals and testes 
showing for the first time that the fetal testis expresses 
LRH-1 together with SF-1 and DAX-1. Nevertheless, we 
found no human mutations of  NR5A2/ LRH-1 in our co-
hort of heterozygote  NR5A1/ SF-1 patients or carriers.
 Both LRH-1 and SF-1 are nuclear factors belonging to 
the NR5A family of transcription factors. Previous in vi-
tro studies have shown that LRH-1 and SF-1 may regulate 
the same cis-elements in promoters [Peng et al., 2003] 
and that they can be differentially regulated themselves, 
thus competing for the same binding sites in target pro-
GAPDH
500 bp
495 bp
512 bp
456 bp
344 bp
302 bp
510 bp
592 bp
454 bp
DAX-1
SF-1
LRH-1 TV4
LRH-1 TV3
LRH-1 TV2
LRH-1 TV1
LRH-1 TV1
tLRH-1
Transcript Adrenaladult
Adrenal
fetal
Testis
adult
Testis
fetal
HepG2
RT+
 Fig. 5. Gene expression patterns of LRH-1 (isoforms 1–4), SF-1 
and DAX-1 in human fetal and adult adrenal and testis tissues. 
Semiquantitative RT-PCRs were performed and a representative 
agarose gel picture is shown (n = 3). HepG2 served as positive ex-
perimental control. GAPDH was used as the internal control. 
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moters such as the inhibin α-subunit gene [Weck and 
Mayo, 2006]. Studies in stem cells demonstrated that 
LRH-1 and SF-1 act as key regulators of the steroidogen-
ic lineage in human mesenchymal stem cells and that 
there is a similar time-dependent induction for LRH-1 
and HSD3B2, but not for CYP17A1 [Yazawa et al., 2009].
 Similar to our presented results, other investigators 
also found that SF-1-regulated genes are regulated by 
LRH-1. The effect of LRH-1 and SF-1 on steroid enzyme 
promoters  CYP17A1 and  HSD3B2 involved in androgen 
production was unambiguously stimulatory, although 
some differences in the strength of this effect were seen 
depending on the cell systems and experimental setup 
employed [Wang et al., 2001; Sirianni et al., 2002; Peng et 
al., 2003; Dubé et al., 2009; Yazawa et al., 2011]. We ob-
served a weaker effect of LRH-1 on the  CYP17A1 pro-
moter but a similar effect on the  HSD3B2 promoter when 
compared to SF-1 ( fig. 2 ). We also observed that using 
longer promoter reporter constructs containing more 
putative LRH-1/SF-1 DNA-binding sites influenced the 
transactivation activity measured (data not shown). 
Therefore, only longer promoter constructs were used for 
our study similar to other studies which demonstrated 
that the  CYP17A1 promoter contains at least 3 regulatory 
cis-elements [Yazawa et al., 2009] and the  HSD3B2 at 
least 2 [Peng et al., 2003]. However, it has been shown that 
not all SF-1-binding elements are effective for LRH-1 or 
SF-1 transcriptional modulation, suggesting a more com-
plex regulation [Kim et al., 2004; Weck and Mayo, 2006].
 While the interplay of SF-1 with DAX-1 on transcrip-
tion is well described [Hanley et al., 2001; Iyer and Mc-
Cabe, 2004], less is known on this interplay between 
LRH-1 and DAX-1 [Peng et al., 2003]. Interestingly, we 
found that DAX-1 is a strong repressor of LRH-1-in-
duced transactivation of the  CYP17A1 and a moderate 
repressor of the  HSD3B2 promoter ( fig. 3 ). Differences on 
the effect of DAX-1 may be explained again by the num-
ber of effective DNA-binding sites in the regulated pro-
moters [Hanley et al., 2001]. In addition, it has been 
shown that the binding affinity between the cofactors 
may modulate the transactivation effect, as stronger bind-
ing and effect was demonstrated between DAX-1 and 
SF-1 than for DAX-1 and LRH-1 [Suzuki et al., 2003].
 LRH-1 and SF-1 can only collaborate in tissues where 
they have overlapping expression profiles. We studied 
the expression profile of the 4 reported LRH-1 isoforms 
in human fetal and adult adrenal and testis tissues and 
compared them to SF-1 and DAX-1 expression ( fig. 5 ). 
Overall, LRH-1 is expressed in all human adult and fetal 
adrenals and testes with the highest expression for LRH-
1 isoform 1 when compared to SF-1 and DAX-1. Isoform 
1 was lowest in adult testis and isoforms 2, 3 and 4 were 
low expressed in all examined tissues. Control HepG2 
cells expressed LRH-1 only, but no SF-1 and DAX-1. 
SF-1 is not expressed in adult rat liver [Falender et al., 
2003], whereas DAX-1 has shown mixed results in mouse 
liver [Kawabe et al., 1999; Niakan and McCabe, 2005; 
Nedumaran et al., 2009]. The expression profile of LRH-
1 and its isoforms for different organs, cells and species 
has been described in previous studies with variable re-
sults [Li et al., 1998; Wang et al., 2001; Sirianni et al., 
2002; Peng et al., 2003; Fayard et al., 2004; Pezzi et al., 
2004; Gao et al., 2006, 2007; Dubé et al., 2009; Yazawa et 
al., 2009; Sierens et al., 2010; Kawabe et al., 2013; Zhang 
et al., 2013]. This might be due to the fact that some iso-
forms are only expressed at very low levels, and for tech-
nical reasons, it is not easy to find a PCR strategy for the 
specific isoforms. In our hands, the most challenging was 
isoform 2. Previous studies showed that LRH-1 is ex-
pressed in human adult adrenals [Wang et al., 2001; Siri-
anni et al., 2002; Yazawa et al., 2009], fetal adrenals 
[Wang et al., 2001] as well as human adult testes [Siri-
anni et al., 2002; Yazawa et al., 2009] and ovaries [Peng 
et al., 2003; Yazawa et al., 2009; Zhang et al., 2013]. LRH-
1 expression in human fetal testis is reported in our study 
for the first time; its expression in the developing testis 
has been only shown in rats so far [Guo et al., 2007; Sie-
rens et al., 2010].  Human LRH-1 isoform 4 has only been 
reported recently [Kawabe et al., 2013]. It is described in 
ovarian tissue and cells as a granulosa cell-specific iso-
form (gc-LRH-1) which is not found in HepG2 liver cells 
[Kawabe et al., 2013]. We detected LRH-1 isoform 4 in 
adrenal, testis and liver (HepG2) demonstrating that it is 
not ovary specific. In granulosa cells, isoform 4 was also 
shown to be controlled by an alternate promoter which is 
located upstream of exon 2 and is under the control of 
both SF-1 and gc-LRH-1/isoform 4 [Kawabe et al., 2013]. 
Thus, alternate promoter usage may prompt variable ex-
pression of LRH-1 isoforms.
 Human mutations for  NR5A2 /LRH-1 are not known. 
We searched for LRH-1 mutations in our cohort (11 fam-
ilies, 19 individuals) for subjects harboring heterozygote 
 NR5A1 /SF-1 mutations for explained reasons. We did 
not find disease-causing mutations, but some sequence 
variations which qualify for SNPs when comparing and 
analyzing with genetic data available for the normal pop-
ulation in several data bases ( table 1 ). However, our ge-
netic analysis which focused on exons and boundaries 
may miss (intronic) mutations.
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 Several studies have shown that LRH-1 plays an im-
portant role in female sexual and reproductive function 
[Zhang et al., 2013]. LRH-1 is differentially expressed in 
the female reproductive system [Falender et al., 2003; 
Zhang et al., 2013] and differentially expressed when 
compared to SF-1 [Falender et al., 2003; Fayard et al., 
2004]. Heterozygote  NR5A1  mutations may cause ovari-
an insufficiency [Lourenço et al., 2009; Camats et al., 
2012]. We thought that phenotypical variability in disease 
state may be explained by variable compensation through 
LRH-1. This hypothesis appears supported by our in vitro 
findings, but not by the genetic analysis of our patients. 
Similarly, LRH-1 seems to play a role in male sex develop-
ment and function as it is expressed in fetal and adult 
 testis and it regulates gene expression of  CYP17A1 and 
 HSD3B2, which are essential for androgen production. 
Compared to SF-1, LRH-1 seems to have a partially over-
lapping expression profile in the testis regarding develop-
ment [Pezzi et al., 2004; Guo et al., 2007; Yazawa et al., 
2009; Sierens et al., 2010] and cell specificity [Pezzi et al., 
2004; Sierens et al., 2010], but the exact interplay of both 
transcription factors is not known. Additionally, our 
study clearly shows that LRH-1 cannot compensate fully 
for heterozygote  NR5A1  mutations in humans, although 
this seems possible in vitro. Together with the finding 
that heterozygosity for mutant  NR5A1/ SF-1 in humans is 
able to cause disease while all tested in vitro systems can-
not reflect this state, we still think that a second hit in yet 
another gene could explain the broad phenotype of 
 NR5A1/ SF-1 mutations. Therefore, in the era of next gen-
eration sequencing, we are now conducting exome se-
quencing analyses on several patients with identified 
 NR5A1 /SF-1 mutations in search for other candidate 
genes which may solve the conundrum of the broad phe-
notype in these DSD patients.
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